D‐1553: A novel KRAS(G12C) inhibitor with potent and selective cellular and in vivo antitumor activity

D‐1553 is a small molecule inhibitor selectively targeting KRAS(G12C) and currently in phase II clinical trials. Here, we report the preclinical data demonstrating antitumor activity of D‐1553. Potency and specificity of D‐1553 in inhibiting GDP‐bound KRAS(G12C) mutation were determined by thermal s...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Zhe, Weng, Jifang, Niu, Haotao, Yang, Hong, Liu, Rongfeng, Weng, Yan, Zhu, Qingqing, Zhang, Yihong, Tao, Liangshan, Wang, Zhenwu, Huh, Seok Jae, Jiang, Yueheng, Mei, Hong, Dai, Xing, Zhang, Ling, Wang, Yaolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323112/
https://www.ncbi.nlm.nih.gov/pubmed/37158138
http://dx.doi.org/10.1111/cas.15829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323112/
https://www.ncbi.nlm.nih.gov/pubmed/37158138
http://dx.doi.org/10.1111/cas.15829

Ejemplares similares